PMID-39225556 – Pharmacotherapy for Cancer Cachexia Network Meta-Analysis
Chen H et al. "Pharmacotherapy for cancer cachexia: a network meta-analysis of randomized controlled trials," Cancer Medicine, 2024;13(18):e70166. doi:10.1002/cam4.70166
Quick Reference
| Property | Value |
|---|---|
| PMID | 39225556 |
| DOI | 10.1002/cam4.70166 |
| Year | 2024 |
| Journal | Cancer Medicine |
| Study Type | Network Meta-Analysis |
| Evidence Level | I |
| Sample | Multiple RCTs across pharmacotherapy classes for cancer cachexia |
| Peptide(s) Studied | Anamorelin (ghrelin axis), megestrol acetate, corticosteroids, thalidomide, and other cachexia interventions |
Key Findings
- Network meta-analysis comparing all major pharmacotherapy classes for cancer cachexia, enabling indirect comparisons between agents never tested head-to-head
- Anamorelin 100mg demonstrated the most favorable weight gain profile: +2.36 kg weighted mean difference vs placebo
- Among all interventions evaluated, anamorelin had the most consistent evidence base for body weight improvement
- Megestrol acetate also showed weight gain but with a less favorable safety profile (thromboembolic events, adrenal suppression)
- Corticosteroids provided short-term appetite stimulation but lacked durable weight effects and carried significant long-term risks
- The network analysis ranked anamorelin as a top-tier pharmacotherapy for cancer cachexia body composition, though functional outcomes remained unimproved across all drug classes
- No single intervention demonstrated superiority across all cachexia endpoints (weight, function, survival, quality of life)
Study Design
Bayesian network meta-analysis of RCTs evaluating pharmacotherapy for cancer cachexia. Included trials of ghrelin-axis agonists (anamorelin), appetite stimulants (megestrol acetate), corticosteroids, thalidomide, anti-inflammatories, and other agents. Network geometry allowed indirect comparisons. Outcomes assessed included body weight change, lean body mass, grip strength, appetite, and adverse events.
Limitations
- Network meta-analysis relies on transitivity assumption (indirect comparisons valid only if trial populations are comparable)
- Heterogeneity in cachexia definitions, cancer types, and staging across network nodes
- Most evidence concentrated in anamorelin and megestrol nodes; some drug classes had sparse data
- Unable to assess combination therapy effects, as most trials studied monotherapy
- No survival endpoint included in the network
Clinical Relevance
This network meta-analysis provides the broadest comparative efficacy landscape for cancer cachexia pharmacotherapy. The finding that anamorelin 100mg produces the largest weight gain (+2.36 kg) positions ghrelin-axis stimulation as the leading pharmacological approach for cachexia body composition. However, the universal failure of all drug classes to improve functional outcomes underscores that cancer cachexia is a multifactorial syndrome requiring integrated, multimodal management beyond any single agent.
Related
#research #meta-analysis #evidence-level-I #cancer